ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) announced its participation in the 36th Annual Piper Sandler Healthcare Conference. President and CEO Nikhil Lalwani and CFO Stephen Carey will host a fireside chat on Wednesday, December 4, 2024, at 3pm EST in New York City.
The event will be available via live webcast and can be accessed through the company's website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. A replay will remain accessible for 90 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – ANIP
In the trading session that priced this news, ANIP gained 2.64%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC.
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: ANI Pharmaceuticals, Inc.
